Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 4/20 | 0.34 |
| ▸ | PRKCA | P17252 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5432523 | 0.93 | MAOB (0.37) | DDR1MAOBADORA2AMAOACDK1 | |
| SCHEMBL5429529 | 0.92 | DDR1 (0.38) | DDR1MAOBMEN1KMT2AMAOA | |
| SCHEMBL5768791 | 0.87 | DDR1 (0.37) | DDR1MAOBADORA2ANPSR1ALDH1A1 | |
| SCHEMBL5437261 | 0.86 | MAOB (0.35) | DDR1MAOBADORA2AMEN1KMT2A | |
| SCHEMBL5434705 | 0.85 | DDR1 (0.39) | DDR1MAOBMAOATP53 | |
| SCHEMBL5431686 | 0.84 | MAOB (0.40) | DDR1MAOBMEN1KMT2AMAOA | |
| SCHEMBL5437043 | 0.83 | MAT2A (0.42) | MAOBMEN1KMT2AMAOANPSR1 | |
| SCHEMBL5432034 | 0.81 | NPSR1 (0.41) | MAOBMEN1KMT2AMAOANPSR1 | |
| SCHEMBL5429829 | 0.80 | MAOB (0.50) | MAOBMAOATP53 | |
| SCHEMBL5431222 | 0.79 | MAOB (0.34) | DDR1MAOBMAOATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | claimed |
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | TRPV1, TRPV2, TRPV4 | DDR1 725/4885MAOB 3067/4885ADORA2A 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.